[ad_1]
Hundreds of millions of doses of the potential vaccine have already been reserved. Photo: TASS
The French company Sanofi and the British company GlaxoSmithKline announced the lack of effectiveness of the developed vaccine and postponed its launch. The modified drug should not be expected before the end of 2021. This is stated in a statement from the companies.
The decision was made after the drug in development did not show sufficient efficacy in elderly patients. The developers believe that this may be due to an insufficient concentration of the antigen (a substance that elicits an immune response).
However, studies have shown that people between the ages of 18 and 49 who received the vaccine had the same immune response as those with Covid-19.
The potential availability of the vaccine has been delayed until the fourth quarter of 2021, although it was previously expected to arrive in the first half of the year.
“Product availability is now expected in the fourth quarter of 2021, pending the successful completion of the development plan,” the statement said.
The news surprised many governments, including the EU, the US, Canada and the UK, which have reserved hundreds of millions of doses of the potential vaccine. In summer, the UK authorities signed an agreement to supply 60 million doses of this vaccine.
Earlier, “Strana” wrote that the British from AstraZeneca and the creators of the Russian “Sputnik V” will test the joint use of vaccines.
We also reported that Todurov said what Ukraine should do with the vaccine from the Russian Federation.
